A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Ipragliflozin (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 07 Jun 2017 Biomarkers information updated
- 25 Jan 2017 Status changed from active, no longer recruiting to completed.
- 19 Jul 2016 Planned End Date changed from 1 Oct 2017 to 1 Jan 2017.